Search Results - "Brennscheidt, U"

A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients by Van Cutsem, E., Verslype, C., Beale, P., Clarke, S., Bugat, R., Rakhit, A., Fettner, S. H., Brennscheidt, U., Feyereislova, A., Delord, J.-P

“…Background: Dysregulation of the epidermal growth factor receptor (HER1/EGFR) has been reported in colorectal cancer (CRC). Erlotinib is a potent inhibitor of…”
Get full text

Pharmacokinetics of Tilidine in Terminal Renal Failure by Seiler, K.-U., Jähnchen, E., Trenk, D., Brennscheidt, U., Heintz, B.

“…The aim of the present study was to investigate the pharmacokinetics of tilidine and its metabolites during the dialysis procedure and in the dialysis‐free…”
Get full text

Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2 by Engelhardt, M., Wirth, K., Mertelsmann, R., Lindemann, A., Brennscheidt, U.

“…High-dose interleukin-2 (IL-2) treatment has demonstrated promising antitumour activity in rena cell carcinoma (RCC) and malignant melanoma (MM) and has been…”
Get full text

Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients by Glauser, M.P., Brennscheidt, U., Cornely, O., Grigg, A., Figuera, A., Keyserling, C., Trostmann, U., Welling, L., Tack, K.

“…Objective To assess the efficacy and safety of clinafloxacin as a single agent for the empirical treatment of febrile episodes and bacterial infections in…”
Get full text

Cytokines in clinical cancer treatment trials: methodological aspects by Brennscheidt, U, Lindemann, A

Get more information

Tilidine does not affect human sphincter of Oddi motility—a randomized, controlled study by WEHRMANN, T., RAUSCH, D., SEILER, K. U., BRENNSCHEIDT, U., CASPARY, W. F.

“…Aim: To investigate the effects of intravenous pentazocine and tilidine on sphincter of Oddi motility. Methods: Twenty patients with suspected sphincter of…”
Get full text

Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine by Henschler, R, Brennscheidt, U, Mertelsmann, R, Herrmann, F

“…c-Jun/AP-1 is a transcription factor commonly induced in mammalian cells by serum, phorbol compounds, or peptide growth factors. We show that c-Jun/AP-1 is…”
Get more information

Molecular organization of the human Raf-1 promoter region by BECK, T. W, BRENNSCHEIDT, U, SITHANANDAM, G, CLEVELAND, J, RAPP, U. R

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Dacarbazine and interferon alpha for stage IV malignant melanoma by Tamm, I, Grimme, H, Bergen, E, Simon, J C, Schöpf, E, Mertelsmann, R, Lindemann, A, Brennscheidt, U

“…Based on encouraging reports of improved response rates with the use of dacarbazine (DTIC) in combination with recombinant interferon alpha-2a (rIFN-alpha-2a)…”
Get more information

Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene by STINGL, G, BRÖCKER, E.-B, BIRNSTIEL, M. L, ZATLOUKAL, K, MAASS, G, WAGNER, E, BUSCHLE, M, KEMPE, E.-R, WEBER, H. A, VOIGT, T, MERTELSMANN, R, WOLFF, K, SCHREIBER, S, KÄMPGEN, E, SCHNEEBERGER, A, TRCKA, J, BRENNSCHEIDT, U, VEELKEN, H

Get full text

Pilot study for the evaluation of T-cell-mediated tumor immunotherapy by cytokine gene transfer in patients with malignant tumors by MERTELSMANN, R, LINDEMANN, A, BOEHM, T, BRENNSCHEIDT, U, FRANKE, B, KULMBURG, P, LAHN, M, MACKENSEN, A, ROSENTHAL, F. M, VEELKEN, H

Get full text

Loss of heterozygosity at the c-raf locus in small cell lung carcinoma by Sithanandam, G, Dean, M, Brennscheidt, U, Beck, T, Gazdar, A, Minna, J D, Brauch, H, Zbar, B, Rapp, U R

“…The c-raf-1 oncogene is located at chromosome 3p25, near a region known to be specifically deleted in patients with renal cell carcinoma and small cell lung…”
Get more information

The complete sequence and promoter activity of the human A-raf-1 gene (ARAF1) by Lee, J E, Beck, T W, Brennscheidt, U, DeGennaro, L J, Rapp, U R

“…The raf proto-oncogenes encode cytoplasmic protein serine/threonine kinases, which play a critical role in cell growth and development. One of these, A-raf-1…”
Get more information

raf oncogenes in carcinogenesis by Storm, S M, Brennscheidt, U, Sithanandam, G, Rapp, U R

“…There are three active raf genes in man and at least two in Xenopus and Drosophila. The mammalian c- and A-raf genes have 16 coding exons, which span 40 and 20…”
Get more information

Processing of tumor tissues for vaccination with autologous tumor cells by Lahn, M, Köhler, G, Schmoor, C, Dengler, W, Veelken, H, Brennscheidt, U, Mackensen, A, Kulmburg, P, Hentrich, I, Jesuiter, H, Rosenthal, F M, Fiebig, H H, Sommerkamp, H, Farthmann, E H, Hasse, J, Mertelsmann, R, Lindemann

“…Vaccination with gene-transfected tumor cells has recently been proposed as a new strategy in the immunotherapy of cancer. Since autologous tumor cells provide…”
Get more information

Pharmacokinetics of nortilidine and naloxone after administration of tilidine/naloxone solution or tilidine/naloxone sustained release tablets by BRENNSCHEIDT, Ulrich, SEILER, Klaus-Ulrich, THOMANN, Peter

“…Valoron N is a compound which consists of the prodrug tilidine (CAS 20380-58-9), from which the active metabolite nortilidine is formed by demethylation in the…”
Get full text

Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: FISH results by Felip, E., Rojo, F., Reck, M., Heller, A., Klughammer, B., Maacke, H., Möcks, J., Brennscheidt, U., Gatzemeier, U., Baselga, J.

“…Abstract only 7160 Background: The HER1/EGFR inhibitor erlotinib significantly prolongs survival of patients with previously-treated advanced NSCLC. Methods…”
Get full text

Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib (TALENT) by Gatzemeier, U., Heller, A., Foernzler, D., Moecks, J., Ward, C., de Rosa, F., Sauter, G., Brennscheidt, U.

“…Abstract only…”
Get full text

Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: preliminary results by Felip, E., Rojo, F., Heller, A., Foernzler, D., Valverde, C., Klughammer, B., Ramos, J., Maacke, H., Brennscheidt, U., Baselga, J.

“…Abstract only…”
Get full text

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) by Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., Brennscheidt, U., De Rosa, F., Mueller, B., Von Pawel, J.

“…Abstract only…”
Get full text